Q-omics provides the consensus-scored LY96 profile across patient tissues and cancer cell-line models. LY96 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, LY96 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, LY96 RNA expression shows 22,274 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, KIRC, and GBM as cancer lineages where LY96 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LY96 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LY96 survival associations across molecular data types. LY96 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LY96 RNA expression–survival associations across cancer types. High LY96 expression shows unfavorable associations in UVM, KIRC, KICH, KIRP and LGG, but favorable associations in CESC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for LY96 RNA expression.
This table summarizes LY96 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for LY96. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LY96 shows lower tumor expression in UCEC, COAD and LUSC and higher tumor expression in KIRC, KIRP and HNSC. The KIRC box plot shows higher LY96 RNA expression in tumor versus normal tissue (log2 FC = +1.856, t-test p < 0.001).
This table shows molecular features associated with LY96 in patient tissues and cancer cell lines. In patient samples, LY96 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, LY96 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SOFT_TISSUE.
